Clostridium Difficile Infection

Clostridium difficile is a bacterium that causes diarrhea and more serious intestinal conditions such as colitis.


Programs + Services


Infectious Diseases Clinic

The Infectious Disease Clinic provides care to patients for a wide range of conditions from our general clinic and several comprehensive subspecialty clinics.
More information about programs and services

Doctors + Care Team

Helen W. Boucher, MD, FACP, FIDSA

Helen W. Boucher, MD, FACP, FIDSA

Accepting New Patients

Title(s): Chief, Division of Geographic Medicine and Infectious Diseases; Director, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR); Director, Heart Transplant and Ventricular Assist Device Infectious Diseases Program; Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-8525

Care of immunocompromised patients, transplant-related infections and S. aureus/MRSA infections

View Full Profile for Helen W. Boucher, MD, FACP, FIDSA

David R. Snydman, MD, FACP, FIDSA, FAST

David R. Snydman, MD, FACP, FIDSA, FAST

Title(s): Emeritus Chief, Division of Geographic Medicine and Infectious Diseases; Emeritus Hospital Epidemiologist; Vice Chair for Research Department of Medicine; Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-5788
Fax #: 617-636-8525

General infectious diseases, cytomegaloviruses and transplantation infectious diseases

View Full Profile for David R. Snydman, MD, FACP, FIDSA, FAST

David R. Stone, MD

David R. Stone, MD

Accepting New Patients

Title(s): Attending Physician; Co-Director of the Mycobacteria Treatment Clinic; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-7100

HIV treatment, tuberculosis and atypical mycobacteria care

View Full Profile for David R. Stone, MD

James Hellinger, MD, MSc

James Hellinger, MD, MSc

Accepting New Patients

Title(s): Attending Physician
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-7100

Infectious diseases, HIV/AIDS, travel medicine, HIV/HCV co-infection

View Full Profile for James Hellinger, MD, MSc

Jose A. Caro, MD

Jose A. Caro, MD

Accepting New Patients

LGBTQ Health

Title(s): Attending Physician; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-8525

HIV/AIDS, PrEP, human papilloma virus and anal dysplasia, sexually transmitted infections, general infectious diseases

View Full Profile for Jose A. Caro, MD

Laura Kogelman, MD

Laura Kogelman, MD

Accepting New Patients

LGBTQ Health

Title(s): Director, Infectious Diseases Clinic; Director, Traveler's Health Service; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-7100

HIV, pre-exposure prophylaxis for HIV, post-exposure prophylaxis for blood-borne pathogens, traveler's health and tropical medicine, general infectious diseases

View Full Profile for Laura Kogelman, MD

Natalie E. Nierenberg, MD, MPH

Natalie E. Nierenberg, MD, MPH

Accepting New Patients

Title(s): Medical Director, Inpatient Wound Prevention and Management; Attending Physician; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7761
Fax #: 617-636-3198

Transplant infectious diseases, wound care at the Center for Vascular Medicine, Wound Healing & Hyperbaric Medicine, travel medicine, general infectious disease

View Full Profile for Natalie E. Nierenberg, MD, MPH

Rakhi (Teena) Kohli, MD, MS

Rakhi (Teena) Kohli, MD, MS

Accepting New Patients

Title(s): Attending Physician; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-1580

Transplant infectious diseases, HIV infection and insulin resistance

View Full Profile for Rakhi (Teena) Kohli, MD, MS

Yoav Golan, MD, MS, FIDSA

Yoav Golan, MD, MS, FIDSA

Accepting New Patients

Title(s): Attending Physician; Associate Professor of Medicine, Tufts University School of Medicine
Department(s): Medicine, Geographic Medicine and Infectious Diseases
Appt. Phone: 617-636-7010
Fax #: 617-636-7100

General infectious diseases, C. difficile, infections in immunocompromised hosts, infections in returning travelers

View Full Profile for Yoav Golan, MD, MS, FIDSA

Research + Clinical Trials


ECOSPOR Ill: A Phase 2 Multicenter, RandomizeEd, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI) 

ECOSPOR Ill is a Phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of;:: 3 CDI episodes within 12 months, inclusive of the current episode. This study is designed to demonstrate the superiority of SER-109 versus placebo to reduce recurrence of Clostridium difficile infection (CDI) in adults who have received antibacterial drug treatment for recurrent CDI (RCDI), based on the proportion of subjects experiencing a CDI recurrence requiring antibiotic treatment up to 8 weeks after initiation of treatment. 
More information about research and clinical trials


ECOSPOR IV: An Open-Label Extension of Study SERES-012 Evaluating SER-109 in Adult Subjects with Recurrent Clostridium difficile Infection (RCDI) 

ECOSPOR IV is an open-label extension of Study SERES-012. This study is designed to evaluate the safety, tolerability, and efficacy of a SER-109 treatment regimen in adult subjects 18 years of age or older with recurrent Clostridium difficile infection (RCDI), who received a SER-109 or placebo treatment regimen in Study SERES-012. 
More information about research and clinical trials